

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



BeOne Medicines Ltd.

百濟神州有限公司

(a corporation incorporated under the laws of Switzerland)

(Stock Code: 06160)

POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 11, 2026 AND CHANGE OF DIRECTORS AND BOARD COMMITTEE COMPOSITION

POLL RESULTS OF THE AGM

References are made to the circular (the “**Circular**”) and notice of the 2026 annual general meeting (the “**AGM**”) of BeOne Medicines Ltd. (the “**Company**”) dated April 28, 2026. Unless otherwise defined herein, capitalised terms in this announcement shall have the same meanings as those defined in the Circular.

The Company is pleased to announce that all the resolutions (the “**Resolutions**”) as set out in the Circular were duly passed at the AGM held on June 11, 2026, at 3:30 p.m. (Central European Summer Time). Full text of each of the Resolutions is set out in the Circular and the poll results for the Resolutions are as follows:

Resolutions		Number of votes (%)		
		For	Against	Abstentions
1.	To approve the audited Swiss statutory standalone financial statements and the audited Swiss statutory consolidated financial statements of the Company for fiscal year 2025.	1,026,904,777 99.98%	175,000 0.02%	33,940,732
2.	To approve the appropriation of the accumulated loss for fiscal year 2025.	1,028,050,311 99.98%	180,369 0.02%	32,789,829
3.	To discharge the members of the Board of Directors and the Executive Management Team from liability for activities during the applicable period under Swiss law (“ Resolution 3 ”).	816,696,880 99.67%	2,683,088 0.33%	177,864,348

Resolutions		Number of votes (%)		
		For	Against	Abstentions
4.	(a) To re-elect Dr. Olivier Brandicourt to serve as a director for a term extending until completion of the 2027 annual general meeting.	1,022,508,944 99.44%	5,736,979 0.56%	32,780,986
	(b) To re-elect Dr. Margaret Dugan to serve as a director for a term extending until completion of the 2027 annual general meeting.	1,011,658,169 98.39%	16,567,756 1.61%	32,794,584
	(c) To re-elect Mr. Anthony C. Hooper to serve as a director for a term extending until completion of the 2027 annual general meeting.	997,703,483 97.12%	29,570,339 2.88%	33,746,687
	(d) To re-elect Mr. John V. Oyler to serve as a director for a term extending until completion of the 2027 annual general meeting.	1,013,945,040 98.76%	12,727,593 1.24%	34,347,876
	(e) To re-elect Dr. Alessandro Riva to serve as a director for a term extending until completion of the 2027 annual general meeting.	708,200,626 68.88%	320,024,909 31.12%	32,794,974
	(f) to re-elect Ms. Shalini Sharp to serve as a director for a term extending until completion of the 2027 annual general meeting.	998,811,368 97.21%	28,636,943 2.79%	33,572,198
	(g) to re-elect Dr. Xiaodong Wang to serve as a director for a term extending until completion of the 2027 annual general meeting.	1,022,595,038 99.45%	5,650,686 0.55%	32,774,785
	(h) to elect Dr. Felix J. Baker to serve as a director for a term extending until completion of the 2027 annual general meeting.	856,267,633 83.28%	171,971,786 16.72%	32,781,090
	(i) to elect Ms. Elizabeth F. Mooney to serve as a director for a term extending until completion of the 2027 annual general meeting.	1,028,073,956 99.99%	152,008 0.01%	32,794,545
	(j) to elect Dr. Charles L. Sawyers to serve as a director for a term extending until completion of the 2027 annual general meeting.	1,028,075,907 99.99%	146,090 0.01%	32,804,912

Resolutions		Number of votes (%)		
		For	Against	Abstentions
5.	To re-elect Mr. John V. Oyler as Chairman of the Board of Directors for a term extending until completion of the 2027 annual general meeting.	939,342,084 91.35%	88,905,363 8.65%	32,779,462
6.	(a) To re-elect Dr. Margaret Dugan to serve as a member of the Compensation Committee of the Board of Directors for a term extending until completion of the 2027 annual general meeting.	1,012,836,634 98.50%	15,408,489 1.50%	32,781,786
	(b) To elect Ms. Elizabeth F. Mooney to serve as a member of the Compensation Committee of the Board of Directors for a term extending until completion of the 2027 annual general meeting.	1,028,055,025 99.98%	172,249 0.02%	32,799,635
7.	To elect the law firm of Schweiger Advokatur/Notariat, Dammstrasse 19, 6300 Zug, Switzerland, as the Independent Voting Representative for a term extending until completion of the 2027 annual general meeting.	1,028,087,301 99.99%	150,289 0.01%	32,789,319
8.	To ratify the appointment of Ernst & Young LLP, Ernst & Young and Ernst & Young Hua Ming LLP as the Company's independent auditors for the fiscal year ending December 31, 2026 and to re-elect Ernst & Young AG as the Company's statutory auditor for the fiscal year ending December 31, 2026.	1,052,800,458 99.23%	8,153,634 0.77%	72,817
9.	To authorize the Board of Directors to fix the auditors' compensation for the fiscal year ending December 31, 2026.	1,022,450,031 99.69%	3,162,724 0.31%	35,208,860
10.	To approve, on an advisory basis, the compensation of our Named Executive Officers, as disclosed in the Circular, for the fiscal year ended December 31, 2025.	975,327,100 94.86%	52,877,460 5.14%	32,815,949
11.	To approve the maximum aggregate compensation of the Board of Directors under Swiss law for the applicable period.	980,858,936 95.39%	47,367,478 4.61%	32,793,555

Resolutions		Number of votes (%)		
		For	Against	Abstentions
12.	To approve the maximum aggregate compensation of the Executive Management Team under Swiss law for fiscal year 2027.	1,002,643,669 97.51%	25,565,844 2.49%	32,810,996
13.	To approve, on an advisory basis, the Swiss Statutory Compensation Report for the fiscal year ended December 31, 2025.	982,348,902 95.55%	45,737,832 4.45%	32,933,775
14.	To approve, on an advisory basis, the Swiss Statutory Non-Financial Matters Report for the fiscal year ended December 31, 2025.	1,025,069,639 99.72%	2,879,917 0.28%	33,070,953
15.	(a) To approve an amendment and restatement of the Company's 2016 Share Option and Incentive Plan (" Resolution 15(a) ").	809,531,160 83.81%	156,426,472 16.19%	95,062,877
	(b) To approve the consultant sublimit set out in the Company's amended and restated 2016 Share Option and Incentive Plan (" Resolution 15(b) ").	854,739,119 88.49%	111,218,786 11.51%	95,062,604
16.	To approve an amendment and restatement of the Company's 2018 Employee Share Purchase Plan (" Resolution 16 ").	963,591,745 99.75%	2,384,295 0.25%	95,044,469
17.	To approve, within the parameters of the HK Listing Rules, the granting of a share issue mandate to the Board of Directors to issue, allot or deal with unissued ordinary shares and/or ADSs (including any sale or transfer of treasury shares out of treasury) not exceeding 20% of the total number of issued shares of the Company (excluding treasury shares) as of the date of passing of such resolution up to the next annual general meeting of shareholders of the Company, subject to the conditions described in the Circular.	719,798,378 70.01%	308,382,843 29.99%	32,839,288

Resolutions		Number of votes (%)		
		For	Against	Abstentions
18.	To approve, within the parameters of the HK Listing Rules, the granting of a share repurchase mandate to the Board of Directors to repurchase an amount of ordinary shares (excluding the RMB shares) and/or ADSs, not exceeding 10% of the total number of issued ordinary shares (excluding RMB shares and treasury shares) of the Company as of the date of passing of such resolution up to the next annual general meeting of shareholders of the Company, subject to the conditions described in the Circular.	1,027,638,828 99.95%	562,594 0.05%	32,819,087
19.	To authorize the Company and its underwriters, in their sole discretion, to allocate to Amgen Inc. (“ Amgen ”) up to a maximum amount of shares in order to maintain the same shareholding percentage of Amgen (based on the then-outstanding share capital of the Company) before and after the allocation of the corresponding securities issued pursuant to an offering conducted pursuant to the general mandate set forth above for a period of five years, which period will be subject to an extension on a rolling basis each year, conditional on the approval of the shareholders who are not Amgen, subject to the conditions described in the Circular (“ Resolution 19 ”).	458,477,301 58.05%	331,297,958 41.95%	271,245,250
20.	To approve the adjournment of the Annual Meeting by the chairman, if necessary, to solicit additional proxies if there are insufficient votes at the time of the Annual Meeting to approve any of the proposals described above.	761,069,153 71.74%	299,855,418 28.26%	95,938

Notes:

- (1) As of May 22, 2026 (the “**Record Date**”), the total number of ordinary shares of the Company issued and outstanding was 1,446,266,956, which excluded (a) ordinary shares issued to the depositary in exchange for a corresponding amount of ADSs for the purposes of ensuring that it has ADSs readily available to satisfy the vesting of restricted share units and the exercise of share options from time to time and (b) ordinary shares held by BG NC 2, Ltd for the benefit of the grantees for the purpose of satisfying outstanding equity awards granted by the Company pursuant to the 2016 Share Option and Incentive Plan (as amended and restated from time to time), which are not considered to be outstanding under the laws of Switzerland.
- (2) The total number of ordinary shares entitling the holders to attend and vote for or against or abstain from voting in respect of the Resolutions (except Resolutions 3, 15(a), 15(b), 16 and 19, in relation to which voting restrictions apply, as further set out in below notes to these Resolutions) at the AGM was 1,446,266,956 ordinary shares.
- (3) As referred to in the Circular, Swiss law provides that members of the Board of Directors and the Executive Management Team and their representatives and entities controlled by them are not entitled to vote on Resolution 3. Members of the Board of Directors and the Executive Management Team and their representatives and entities controlled by them were interested in 64,515,971 ordinary shares of the Company (excluding shares underlying outstanding share options, restricted share units and performance share units), representing approximately 4.46% of the total issued and outstanding share capital of the Company as of the Record Date. Accordingly, the total number of ordinary shares entitling the other shareholders to attend and vote for or against or abstain from voting in respect of Resolution 3 at the AGM was 1,381,750,985 ordinary shares.
- (4) As referred to in the Circular, Mr. John V. Oyler and Dr. Xiaodong Wang, together with their associates, were required to abstain and did refrain or abstain from voting to approve Resolutions 15(a), 15(b) and 16. Mr. John V. Oyler and Dr. Xiaodong Wang, together with their associates, were interested in 62,254,972 ordinary shares of the Company (excluding shares underlying outstanding share options, restricted share units and performance share units), representing approximately 4.30% of the total issued and outstanding share capital of the Company as of the Record Date. Accordingly, the total number of ordinary shares entitling the other shareholders to attend and vote for or against or abstain from voting in respect of Resolutions 15(a), 15(b) and 16 at the AGM was 1,384,011,984 ordinary shares. For the purpose of calculating the scheme mandate limit under the HK Listing Rules, the total number of ordinary shares of the Company in issue as at the date of the AGM (being June 11, 2026) was 1,541,419,108, which excluded ordinary shares issued to the Company’s depositary in exchange for a corresponding amount of ADSs for the purpose of ensuring that the ADSs are readily available to satisfy the vesting of restricted share units and the exercise of share options from time to time but included ordinary shares held by BG NC 2, Ltd for the benefit of the grantees for the purpose of satisfying outstanding equity awards granted by the Company pursuant to the 2016 Share Option and Incentive Plan (as amended and restated from time to time), which are not considered to be outstanding under the laws of Switzerland.
- (5) As referred to in the Circular, Amgen was interested in 246,269,426 ordinary shares of the Company, representing approximately 17.03% of the total issued and outstanding share capital of the Company as at the Record Date, and was required to refrain or abstain and did refrain or abstain from voting on Resolution 19. Accordingly, the total number of ordinary shares entitling the other shareholders to attend and vote for or against or abstain from voting in respect of Resolution 19 at the AGM was 1,199,997,530 ordinary shares.
- (6) Save as disclosed above, there were no shares entitling any holder to attend and being required to abstain from voting in favor of any of the Resolutions at the AGM as set out in Rule 13.40 of the HK Listing Rules, and no other shareholder was required to abstain from voting at the AGM under the HK Listing Rules.
- (7) No other shareholders have stated their intention in the Circular to vote against or to abstain from voting on any of the Resolutions.
- (8) As a simple majority of the votes were cast in favor of the Resolutions, the Resolutions were duly passed.
- (9) Computershare Switzerland Ltd. was appointed as the scrutineer at the AGM for the purpose of vote-taking. Mr. John V. Oyler, Dr. Xiaodong Wang, Dr. Olivier Brandicourt, Dr. Margaret Han Dugan, Mr. Anthony C. Hooper, Dr. Alessandro Riva, Dr. Corazon (Corsee) D. Sanders and Ms. Shalini Sharp attended the AGM.

CHANGE OF DIRECTORS AND BOARD COMMITTEE COMPOSITION

Reference is made to the announcement of the Company dated April 17, 2026 (the “**Announcement**”) in respect of the director nominees and proposed changes in board committee composition.

With effect from the conclusion of the AGM, Mr. Michael Goller, Mr. Ranjeev Krishana, Dr. Corazon (Corsee) D. Sanders and Mr. Qingqing Yi ceased to serve on the Board and the respective Board committees. Dr. Felix J. Baker, Ms. Elizabeth F. Mooney and Dr. Charles L. Sawyers (the “**New Directors**”) were elected and Mr. John V. Oyler, Dr. Xiaodong Wang, Dr. Olivier Brandicourt, Dr. Margaret Han Dugan, Mr. Anthony C. Hooper, Dr. Alessandro Riva and Ms. Shalini Sharp were re-elected as the directors of the Company. The biographical details of the New Directors are set out in the Announcement and the Circular. As of the date of this announcement, there have been no changes to the biographical details of the New Directors.

The Company further announces the proposed changes in composition of board committees set out in the Announcement took effect from the conclusion of the AGM.

By order of the Board
BeOne Medicines Ltd.
Mr. John V. Oyler
Chairman

Hong Kong, June 12, 2026

As of the date of this announcement and after the conclusion of the AGM, the Board of Directors of the Company consists of Mr. John V. Oyler as Chairman and Executive Director, Dr. Felix J. Baker and Dr. Xiaodong Wang as Non-executive Directors, and Dr. Olivier Brandicourt, Dr. Margaret Han Dugan, Mr. Anthony C. Hooper, Ms. Elizabeth F. Mooney, Dr. Alessandro Riva, Dr. Charles L. Sawyers and Ms. Shalini Sharp as Independent Non-executive Directors.